SciTegic’s ISV Partner Program Welcomes Twentieth Member
News Jan 11, 2006
SciTegic has announced that four new members have joined its Independent Software Vendor (ISV) partner program.
The program’s aim is to compile a collection of high value research applications to address customer needs for increased software interoperability.
Through new collaborations with ACD/Labs, Bio-Rad, GeneGo, and Partek, scientists in drug discovery will obtain access to integrated software products that will help them solve complex research problems in an efficient manner.
"We are pleased to see a rapidly growing community adopt the Pipeline Pilot platform for life sciences software deployment," says Mathew Hahn, Vice President and General Manager of SciTegic.
"By promoting partnerships with key scientific software vendors, we allow our customers to leverage existing, specialized software solutions in order to increase their R&D productivity."
"Our joint customers will be able to access ACD/Labs' PhysChem and Nomenclature batch software from within SciTegic's Pipeline Pilot framework, leading to more efficient and repeatable discovery processes," says Antony Williams, Vice President and Chief Science Officer of ACD/Labs.
"The combination of our KnowItAll® technologies for in silico ADME/Tox with SciTegic will allow drug discovery researchers to more accurately predict key properties for potential drug candidates, thus accelerating the drug discovery process," says Gregory M. Banik, Ph.D., General Manager of Bio-Rad Laboratories, Informatics.
"We are excited to deliver our technology as part of SciTegic’s Pipeline Pilot platform," says Julie Bryant, Vice President of Business Development of GeneGo.
"Joint customers will be able to increase their research efficiency by rapidly incorporating pathway information in their workflows."
"We are pleased to join SciTegic’s ISV program," said Tom Downey, President and CEO of Partek.
"As it allows us to bring together the data workflow capabilities of Pipeline Pilot with the statistics and interactive visualization capabilities that our software offers, allowing life sciences researchers to make better decisions."
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.